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Introduction
The measurement of 25- (5) . In addition to its wellknown effects on bone and mineral metabolism, low 25(OH)D concentration has been associated with glucose intolerance (6, 7) , type 2 diabetes (8) , insulin resistance (9) , hypertension (10), hyperlipidemia (11) , and cardiovascular disease (9, 12) . Therefore, in addition to reflecting the relation of 25(OH)D to bone health, guidelines for interpreting 25(OH)D concentration should take into account the relation of 25(OH)D to non-bone end points. A threshold, if one exists, defining 2 regions, 1 in which 25(OH)D is related to metabolic outcome and another in which there is no relation, could help define the normal range.
At least in part because of increased skin melanin, blacks are at higher risk of vitamin D deficiency than whites (13) . Although 25(OH)D concentration is known to be less strongly associated with bone health in blacks compared with whites (14) , little is known about race-related differences in the relation between 25(OH)D and non-bone-related physiologic variables. Individuals who are obese are at increased risk of vitamin D deficiency (15) , type 2 diabetes (6), and cardiovascular disease (16) . Therefore, obese individuals constitute an ideal population in which to study the association of 25(OH)D with measures of glucose tolerance, insulin resistance, and other risk factors for cardiovascular disease. Our study had 2 goals: 1) to examine the association between 25(OH)D and measures of glucose tolerance, insulin resistance, and other cardiovascular risk factors in overweight and obese postmenopausal women; and 2) to determine whether the associations differ by race.
Participants and Methods
Participants. We studied 239 (83 black, 156 white) ( (17) (18) (19) . The data used in this report were obtained during baseline testing for the studies. At the time the data were gathered, the only intervention the participants received was 6-8 wk of an AHA diet (20) designed to stabilize weight and metabolic variables. The study reported here was approved by the University of Maryland Institutional Review Board.
Body composition [fat-free mass (lean mass + bone mass) and percentage fat] was measured by DXA. Over the time period of the 8 studies that contributed data to the present analysis, 3 DXA scanners were used (DPX-L, DPXIQ, and Prodigy; all manufactured by GE LUNAR Radiation). The scanners were cross-calibrated to ensure that they gave comparable measurements. Visceral and subcutaneous abdominal fat was determined from a single computed tomography image obtained at the level of the second and third lumbar vertebral body as previously ] was measured during a graded treadmill exercise stress test during which oxygen utilization and CO 2 production were continuously measured (23) . Fasting plasma glucose and fasting plasma insulin (I 0 ) concentrations were measured at the beginning of a 2-h, 75-g oral glucose tolerance test conducted in the morning after a 10-h overnight fast. Twohour plasma glucose and insulin concentrations were measured at the end of the test. Plasma glucose concentration was measured using a glucose oxidase assay; plasma insulin concentration was measured by RIA. Plasma lipid concentrations were measured using an automated colorimetric assay. HDL concentration was measured in the supernatant after precipitation of VLDL, IDL, and LDL with dextran sulfate (24) . LDL concentration was computed from total cholesterol, HDL, and TG concentrations using the Friedewald equation (25) . Reported lipid concentrations are the mean of 3 plasma samples taken while the participant was metabolically stable over a period of 2.6 (1.4-3.9) wk [median (25th-75th percentiles)]. 25(OH)D, parathyroid hormone (PTH), and insulin-like growth factor-1 (IGF-1) were measured specifically for this report, from a single plasma aliquot that had been stored at 280°C for 0-13.8 y [7.5 (2.9-9.6) y; median (25th-75th percentiles)]. We report the mean of 2 measurements from each aliquot. Samples that had evidence of evaporation or crystallization were not assayed. Plasma PTH was measured using immunoradiometric assay [Nichols Institute Diagnostics assay, sensitivity: 1.0 pg/ mL (1 ng/L); intra-assay CV: 4.09%; interassay CV: 4.94%], plasma IGF-1 was measured using RIA [Nichols Institute Diagnostics assay, sensitivity: 0.1 mg/L (0.013 nmol/L); intra-assay CV: 7.15%; interassay CV: 9.63%]. Plasma 25(OH)D was measured using RIA [Diasorin assay, sensitivity: 3.0 mg/L (7.5 pmol/L); intra-assay CV: 5.19%; interassay CV: 7.90%].
Statistical methods. Analyses started with exploratory data analysis looking for extreme values. Extreme values were checked to ensure that they were not the result of transcription or other errors. This was followed by visual inspection of bivariate plots depicting the association of 25(OH)D with each of our study variables (Tables 2 and 3) . Each plot included a smoothing spline fit to the data. Several of the plots suggested a critical 25(OH)D concentration of ;25 ng/dL (62.5 pmol/L) defining 2 regions-1 above and 1 below a critical value (knot)-such that, below the knot, the slope was steeper than that above the knot. For each nonobesity outcome (Table 3) , we performed a piece-wise linear regression with a single knot (SAS proc nlin), adjusted for race, age, and time (days), plasma was stored prior to 25(OH)D assay. The regressions, performed with no a priori assumption about the location of the knot, were run to determine objectively if a knot existed, the location of the putative knot, and the slopes above and below the knot. [There were no statistically significant race 3 25(OH)D interactions.] For 4 outcome measures-2-h glucose, I 0 and 2-h insulin, and HOMA-IR-evidence of a knot was found. For these outcomes, to determine whether the existence of a knot would survive additional adjustment, multiple variable piecewise continuous linear regressions were run (SAS proc GLM) in which the 25(OH)D concentration at which the knot was observed defined 2 straight lines: 1 below the knot and a second above the knot ( Table 4) . These analyses (and all other regressions unless otherwise noted) were adjusted for age, race, month plasma was obtained for 25(OH)D assay, time (number of days) plasma was stored before 25(OH)D, PTH, and IGF-1 assay, percentage fat (by DXA), and, depending on the outcome variable, the use or non-use of drug therapy for hyperlipidemia (outcome lipids), hypertension (outcome blood pressure), or postmenopausal hormonal replacement (outcome measures glucose, insulin, and HOMA-IR). To allow our results to be compared with studies that did not look for a critical 25(OH)D threshold, for each non-obesity outcome variable, we performed a multiple variable linear regression looking for a single slope relating 25(OH)D to the outcome variable (Table 3) . To determine whether IGF-1 modulated the relation between 25(OH)D and outcome, we performed additional analyses in which IGF-1 and an IGF-13 25(OH)D interaction were added to the multiple variable piecewise continuous linear regressions and the single-slope multiple-variable linear regressions. For the single-slope multiple-variable linear regressions, 2 terms were added to the model: 1) IGF-1; and 2) IGF-1 3 25(OH)D. The single-slope multiple-variable linear regressions were as follows:
where . represents terms for intercept, age, race, month plasma was obtained for 25(OH)D assay, time (number of days) plasma was stored before 25(OH)D, PTH, and IGF-1 assay, and other adjustments as For the piecewise continuous linear regressions, IGF-1 and 2 interactions were added to the model: 1) the product of vitamin D below the knot and IGF-1; and 2) the product of IGF-1 and the difference between the IGF-1 slopes above and below the knot. The piecewise continuous linear regressions were as follows: For the multiple-variable piecewise continuous linear regressions, these computations were performed separately for the line below and above the knot. Because not all participants had every outcome measured, the number of participants reported varies by outcome. A 2-tailed P < 0.05 was considered significant.
Results
Clinical characteristics of study participants. The 83 black women on average were younger and more obese (higher BMI and percentage fat), had a greater waist circumference, had more subcutaneous abdominal fat [and a higher proportion of their total abdominal fat (subcutaneous + visceral) was subcutaneous], had lower fitness (lower VO 2 max), and had lower 25(OH) D concentration than the 156 white women (Table 1 ). These differences were unchanged after adjustment for age (data not shown). According to the 25(OH)D cut points defined by the IOM (4), 62% of the black participants had either an insufficient (40%) or deficient (22%) 25(OH)D concentration compared with 27% of the whites (23% insufficient, 4% deficient) (Fig. 1) . If the $30 mg/L concentration (75 nmol/L) defined by the Endocrine Society (3) is accepted as normal, 92% of the black and 76% of the whites would be classified as having an abnormal 25(OH)D concentration. Plasma PTH concentration was higher in blacks than whites (P < 0.002). There was no evidence of a significant difference in IGF-1 concentration in blacks vs. whites (Table 1) . There was no difference by race in the percentage of participants who had impaired fasting glucose (blacks: 30%, 24 of 81 vs. whites: 28%, 43 of 155; P < 0.76) or impaired glucose tolerance (blacks: 43%, 34 of 80 vs. whites: 36%, 55 of 155; P < 0.29). Despite this, blacks had higher I 0 and 2-h insulin concentrations and greater insulin resistance (higher HOMA-IR) than whites (Table 1) Table 2 ). The waist-to-hip ratio and subcutaneous fat area were not significantly related to 25(OH)D concentration. Blacks had lower 25(OH)D concentrations than whites independent of age, percentage fat, the various measures of body composition, or VO 2 max (race term; all P < 0.01) ( Table 2 ). PTH did not affect the association of the measures of obesity or VO 2 max with 25(OH)D, and there were no significant interactions with PTH (data not shown).
Plasma 25(OH)D as a predictor of metabolic and physiologic measures: single-slope linear regression. Plasma 25(OH)D concentration was a significant predictor of glucose concentration and insulin resistance (all slopes P # 0.04 except 2-h glucose, P < 0.093) and a significant predictor of PTH concentration (P < 0.01) ( Table 3 ). The slopes were all negative, indicating that measures of glucose-insulin physiology improved (i.e., decreased) and that PTH decreased with increasing 25(OH)D concentration. 25(OH)D concentration was unrelated to blood pressure, IGF-1 (P < 0.071), or lipids other than TGs. There was no evidence of different slopes relating 25(OH)D to any of the physiologic measures studied in blacks and whites [all race 3 25(OH)D interaction terms were nonsignificant and were dropped from the models]. At any 25(OH)D concentration, fasting plasma glucose concentration and TG concentration were significantly lower and I 0 was significantly higher in blacks than whites (race term) ( Table 3) . IGF-1 modulated the relation between 25(OH)D and both I 0 and insulin resistance (HOMA-IR). When IGF-1 and an IGF-1 3 25(OH)D interaction were added to the equation predicting logI 0 , the interaction was almost significant (P < 0.052). When the interaction was added to the equation predicting logHOMA-IR, the interaction was of borderline significance (P < 0.073). PTH, and IGF-1 assays were performed percentage fat, race, and postmenopausal hormone replacement therapy. 3 Computed from the coefficients returned by the piecewise continuous linear regression and the variance-covariance estimates of the parameters. 4 Slope above knot minus slope below knot. PTH. PTH had a moderate, statistically significant correlation with 25(OH)D (r = 20.35, P < 0.001). When PTH alone or a PTH 3 25(OH)D interaction was added to the models (multiplevariable linear regression or piecewise continuous regression), there was no evidence of PTH, either as a main effect or an interaction, having a significant effect on the outcome measures studied (data not shown).
Discussion
We found in postmenopausal, overweight and obese women without diabetes that low 25(OH)D was associated with elevated glucose concentration and increased insulin resistance. To the best of our knowledge, this is the first study to report evidence of a threshold effect of 25(OH)D with these measures. As discussed below, our findings suggest that there is no need for race-specific vitamin D cut points defining normal vs. whites. Although we found that, for a given 25(OH)D concentration, fasting glucose and TG concentrations were lower and I 0 and HOMA-IR were higher in blacks than whites (race term) (Table 3) , the race-related differences were small and of minimal biologic importance. These findings suggest that, at least for non-bone-related outcome measures, there is no need for racespecific definitions of normal vs. abnormal 25(OH)D concentration; the same cut points can be used in blacks and whites. It is possible that our inability to find any race 3 25(OH)D interactions was a Type II error (failure to identify a true effect). To the best of our knowledge, our study is the first to look for racerelated differences in the relation between 25(OH)D and the nonbone-related outcome measures. Larger studies will be needed to confirm our findings. Glucose metabolism and insulin resistance in blacks and whites. Consistent with our previous reports from 3 (17, 18, 21) of the 7 studies that contributed participants to the present study and as reported by others (28), we demonstrate that middle-aged black women have lower fasting glucose concentration, higher I 0 concentrations, and higher HOMA-IR than whites of the same age. This study extends these findings by showing that the lower fasting glucose concentration, higher I 0 concentrations, and higher HOMA-IR in blacks than whites are not caused by the (32) . Vitamin D reduces inflammatory processes (33) , resulting in improved insulin sensitivity (34) , and has been shown to reduce inflammation after coronary events (35) . Conversely, low 25(OH)D raises PTH concentration, which is associated with insulin resistance in healthy adults (36) .
Body composition predicting 25(OH)D. In this study and in our previous work (17, 18, 21) , we found that black women compared with white women of the same age had greater adiposity (BMI, percentage fat) and larger waist circumference and that a higher proportion of their abdominal fat was stored in the subcutaneous, compared with the visceral, compartment. We found that BMI, waist circumference, percentage fat, and visceral fat, but not subcutaneous abdominal fat or waist-tohip ratio (Table 2) , predicted 25(OH)D.
Although others report inverse associations between 25(OH) D and subcutaneous fat (37) , the physiology underlying the association is not fully understood. It has been suggested that 25(OH)D is sequestered in adipose tissue (15) , resulting in lower circulating 25(OH)D with increasing body fat. Drincic et al. (38) propose another explanation for the inverse ratio: volumetric dilution. They propose that 25(OH)D is not sequestered within fat but passively diffuses into and out of adipose tissue based on an equilibrium between blood 25(OH)D (bound to D-binding protein) and 25(OH)D within body fat depots. Our finding that the slopes relating measures of obesity and regional adiposity to 25(OH)D were similar in blacks and whites (Table 2) suggests that changes in body composition have similar effects on 25(OH)D in black and white women. The statistically significant and negative race term indicating that 25(OH)D concentration is lower in blacks than whites for a given amount of visceral or subcutaneous abdominal fat suggests that vitamin D is stored differentially in different fat depots in blacks and whites.
Storage before assay. The plasma used in our 25(OH)D, IGF-1, and PTH assays was stored at 280°C for up to 13.8 y [7.5 (2.9-9.6) y; median (25th-75th percentiles)] before assay. All other biochemical assays were run shortly after plasma was obtained. We have 2 reasons to believe that the storage time did not affect our results. First, to see whether storage time affected our results, we compared results from analyses in which we controlled for time of storage vs. analyses in which we did not control for time of storage. The results of the 2 sets of analyses were remarkably similar; inferences derived from the 2 sets of analyses were the same. Second, 25(OH)D has been shown to be stable in long-term frozen storage. Serum 25(OH)D concentrations measured from frozen samples stored from 6-24 y showed practically no correlation with storage time (39) . IGF-1 is also stable in storage. Serum values of IGF-1 obtained from serum stored for 9 years at 280°C were similar to concentrations found in freshly collected sera (40) . The long-term stability of PTH is more controversial. A comparison of PTH concentrations obtained from samples stored in EDTA tubes for 5 y with matched controls found no significant difference between the concentrations (41) . In contrast, a 27% decrease in PTH was found in serum samples stored for 10 mo and subjected to 1 freeze-thaw cycle before analysis (42) .
In summary, we report an inverse relation between 25(OH)D and fasting plasma glucose, I 0 and 2-h insulin, HOMA-IR, and TGs and found evidence for a threshold effect of 25 Additional studies are needed to confirm that our results hold in other populations, including other racial and ethnic groups (e.g., Hispanics and Asians), studies in men, and studies in younger and older participants. A large, prospective interventional study in black and white women will be needed to confirm that increasing 25(OH)D concentration above ;26 mg/L (65.0 pmol/L) improves glucose homeostasis and insulin sensitivity with little improvement above this value.
